VIR-5500 targets PSMA and is being tested in a phase 1 trial for mCRPC, including combination therapy with ARPIs. Interim data showed PSA reductions in all patients and a favorable safety profile, ...

Men who are further along in their fertility journey were found to be less likely to be using testosterone, according to recent data presented at the 26h Annual Fall Scientific Meeting of the Sexual ...

An expert discusses how his diagnostic treatment workflow for a new patient with benign prostatic hyperplasia (BPH) progresses from initial α-blocker therapy through noninvasive systematic testing ...

CAN-2409 plus valacyclovir significantly improved disease-free survival compared with placebo plus valacyclovir. Phase 3 data from the PrTK03 trial (NCT01436968) were recently presented at the ...

Findings showed that although most applicants emphasized work ethic and interpersonal skills, these attributes were not predictive of receiving an interview invitation. In this video, Sevann Helo, MD, ...

Casdatifan showed a 35% confirmed ORR in the 100 mg cohort, with median PFS not reached, indicating promising efficacy. The pooled analysis revealed a 31% ORR and a median PFS of 12.2 months, ...

Flibanserin received FDA priority review for expanded use in postmenopausal women with hypoactive sexual desire disorder, building on its 2015 approval for premenopausal women. Gepotidacin was ...

Melvin L.K. Chua, FRCR, PhD, FASCO, highlights data validating the performance of the ArteraAI Prostate test in an Asian cohort of patients with prostate cancer. “Nivolumab, combined with standard of ...

The Virtuoso Surgical Robotic System received FDA breakthrough designation for bladder lesion removal, enabling expedited development and review processes. En bloc resection improves cancer staging ...

The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...

The FDA approved subcutaneous pembrolizumab and berahyaluronidase alfa-pmph for solid tumors in patients 12 years or older. Recommended dosages are 395 mg/4800 U every 3 weeks or 790 mg/9600 U every 6 ...

Carotuximab and apalutamide combination shows over 13 months median PFS in mCRPC, surpassing the 45% improvement threshold. Interim safety analysis reveals the regimen is well-tolerated, with no ...